IP Library Granted Patent US 10,221,462
Granted Patent B2
US 10,221,462 · App. 15/649,969 · Granted Mar 5, 2019

Single nucleotide polymorphisms and community-associated methicillin-resistant

Inventors: Scott E. Gygax (Yardley, PA); Sean Chadwick (Florence, NJ); Aditya Prasad (Marlton, NJ); Martin E. Adelson (East Windsor, NJ); Eli Mordechai (Robbinsville, NJ)
Assignee: Medical Diagnostic Laboratories, LLC.
C12Q1/689C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,221,462
App. No.
15/649,969
Granted
Mar 5, 2019
Kind
B2
Abstract

The present invention is based on the discovery of polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus . The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.

Claims (3)

1. A kit for detecting the presence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) in a human, comprising:

(a) an allele-specific primer pair comprising a forward primer and a reverse primer for amplifying a region containing a SNP selected from the group consisting of G88A and G2047A of the penicillin binding protein 3 gene to produce an amplicon; and

(b) an instruction of using said allele-specific primer pair in a PCR to determine the presence of said SNP, wherein the presence of said SNP is indicative of the presence of CA-MRSA and said primer pair comprises a forward primer of SEQ ID No. 26 and a reverse primer of SEQ ID No. 36.

Assignments (1)
SECURITY INTEREST Recorded Apr 27, 2018
From: MEDICAL DIAGNOSTIC LABORATORIES, L.L.C.
To: TD BANK, N.A.
Reel/Frame 046031/0381 →
Continuity (3)
Division 13068331 · May 9, 2011
Provisional Application 61395130 · May 7, 2010
Related Publication 20170314065A1 · Nov 2, 2017